What happened
Cell Biotech reported consolidated results for FY2025: revenue of US$36.8M (+6.8% year on year), operating profit of US$5.47M (+16.4% year on year) and net income of US$6.61M (−36.7% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$36.8M |
|---|---|
| Revenue vs a year earlier | +6.8% |
| Operating profit | US$5.47M |
| Net income | US$6.61M |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-20, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260220900900 → open original filing |
Source: DART. Information only, not investment advice.